

Travel-Related Tick-Borne Encephalitis, Israel, 2006–2014

Eyal Meltzer,¹ Yael Paran,¹ Yaniv Lustig,
Shmuel Stienlauf, Miriam Weinberger,
Eli Schwartz

During 2006–2014, four tick-borne encephalitis (TBE) cases occurred among Israeli travelers. We calculated TBE incidence at 321.0, 45.0, 13.2, and 7.5 cases/100,000 travelers/year of travel to Sweden, Switzerland, Austria, and Germany, respectively. TBE incidence among travelers to these destinations appears to justify TBE vaccination in accordance with World Health Organization recommendations.

Tick-borne encephalitis (TBE), an arboviral zoonosis transmitted mostly through the bite of *Ixodes* spp. ticks, is endemic to many popular tourist destinations in Europe (1). TBE vaccine is considered immunogenic and safe. It is highly effective in reducing TBE in disease-endemic areas such as Austria, the first country to include the vaccine in its national vaccine program. The World Health Organization (WHO), the US Centers for Disease Control and Prevention, and the Israeli Ministry of Health have published advice on TBE vaccination for travelers (2–4), suggesting limiting vaccination to travelers planning activities with high-risk exposures. However, the evidence base for these recommendations is not well established.

The most comprehensive study of travel-related TBE (5) comprised 38 travel-related cases of TBE and estimated an annual attack rate of 1 case/1.3–2 × 10⁶ travelers. However, the lack of an accurate denominator and absence of data on exposure time raise questions about its accuracy. We investigated the epidemiology of TBE in travelers from Israel and assessed the risk for travel-related TBE.

The Study

In Israel, viral encephalitis is a notifiable disease. Diagnostic tests for TBE in Israel have been available since 2006 and are performed only in the Israeli Central Virology Reference Laboratories (Tel Hashomer, Israel) of the Israeli Ministry of Health by using an indirect immunofluorescence

Author affiliations: Chaim Sheba Medical Center, Tel Hashomer, Israel (E. Meltzer, Y. Lustig, S. Stienlauf, E. Schwartz); Tel Aviv University, Tel Aviv, Israel (E. Meltzer, S. Stienlauf, M. Weinberger, E. Schwartz); Tel Aviv Sourasky Medical Center, Tel Aviv (Y. Paran); Assaf Harofeh Medical Center, Zerifin, Israel (M. Weinberger)

DOI: <http://dx.doi.org/10.3201/eid2301.160888>

commercial kit (Euroimmun AG, Lübeck, Germany) according to manufacturer instructions.

As numerator, we included all confirmed cases of TBE (according to criteria adopted by the European Commission in 2012 [6]). During 2006–2014, a total of 4 TBE cases were diagnosed in Israel: 1 case each acquired in Austria, Russia, and Sweden and 1 case acquired in either Germany or in Switzerland (Table 1; online Technical Appendix, <http://wwwnc.cdc.gov/EID/article/23/1/16-0888-Techapp1.pdf>).

As denominator we used 2 sets of data. For the first, in emulation of Steffen et al. (5), we calculated TBE attack rate per 100,000 traveler entries during the study period, according to the number of Israeli tourists obtained from the United Nations World Tourism Organization database (Table 2). Cumulatively, 3,928,164 Israeli travelers had entered these countries during the study period. The combined attack rate for these countries (according to whether Germany or Switzerland was considered the place of acquisition of 1 case) ranged from 1 case per 837,528 to 1 case per 573,493 Israeli tourist entries.

Because the United Nations World Tourism Organization database lacks information about duration of stay, we also used data on the absolute number of nights stayed by Israeli travelers during the study period from the published tourism statistics of Switzerland, Germany, and Austria (10–12) (similar data for Russia were lacking); for Sweden, we obtained the number of overnight stays from Statistics Sweden (E. Meltzer, unpub. data). TBE incidence ranged from 1 case per 697,700 person-weeks (Germany) to 1 case per 16,270 person-weeks (Sweden), which is equivalent to an annual incidence of 7.5–321.0 cases/100,000 travelers per year of travel (Table 2).

Conclusions

TBE is endemic to some of the most popular tourist destinations in developed countries, raising questions about vaccination and advice to travelers. However, there is such a dearth of published research on the actual risk to travelers that TBE is termed a neglected disease in travel medicine (13). A 2016 study of travel-related TBE estimated an attack rate of 1 case per 1.3–2 × 10⁶ tourist-entries, concluding that vaccination should be offered only to travelers planning activities resulting in at-risk exposures (5). By using travel duration data, we found that the actual TBE incidence rate in travelers from Israel to

¹These authors contributed equally to this article.

Table 1. Clinical, epidemiologic, and laboratory data for TBE cases, Israel*

Variable	Case-patient 1	Case-patient 2	Case-patient 3	Case-patient 4
Destination	Austria	Germany, Switzerland	Sweden	Russia
Probable area of exposure	Salzburgland	Baden-Wuerttemberg	Northwest of Stockholm	Southwestern Siberia
Month of travel	2014 Jun	2012 Sep	2011 May–Aug	2010 Aug
Duration of travel, d	3	14	107	17
Duration of probable exposure to tick habitat	1 h	4 d	Undetermined	17
Recorded tick bite	Yes	No	No	No
Neurologic manifestations during acute phase	Diplopia → stupor, aphasia, quadriparesis	Dysphagia, dysgeusia, bilateral facial nerve paralysis	Meningismus, mild confusion, dysarthria → Lt facial nerve. paralysis	Acute confusion, stupor
Neurologic outcome at 6 mo	Complete motor recovery, difficulty in complex tasks, depression.	Complete recovery	Complete recovery	Complete recovery
TBE serology results†				
First serum sample	IgM positive, IgG positive	IgM positive, IgG negative	IgM positive, IgG positive	IgM positive, IgG positive
Convalescent-phase serum sample	IgM positive, IgG 10-fold increase	IgM positive, IgG seroconversion	IgM positive‡, IgG positive‡	ND

*ND, not done; TBE, tickborne encephalitis.

†West Nile virus was ruled out serologically in all cases.

‡Direct comparison between serum samples was not possible because initial sample was taken abroad.

Sweden, Austria, Germany, and Switzerland (Table 2) is at least as high as that of the local population (5/100,000 in Austria and <1/100,000 in Germany, for example [1]) and is higher than the WHO-recommended threshold for universal TBE vaccination (an annual incidence >5/100,000 population) (14).

Few other studies on the incidence of travel-related TBE have been published. These studies also suggest a substantial TBE risk to travelers that is similar in range to our results (Table 2).

Our study has several limitations. Calculating incidence rates when event numbers are small runs the risk for overestimation, according to the law of small numbers. However, by considering the total period of TBE test availability in Israel (9 years), rather than just the years in which cases were detected, we believe we avoided such overestimation. In addition, reporting of notifiable diseases might

be incomplete, and clinicians' awareness of the need to consider TBE in a returning traveler from Europe or northern Asia probably is insufficient. Also, milder TBE cases might have been overlooked. These considerations also might have resulted in an underdetection of cases. Statistics on overnight stays might not include some travelers, such as expatriates in private residences or those staying with families. On the other hand, in such travel scenarios, persons with TBE might have been treated abroad and therefore missed. We believe the combined effect of these limitations is more likely to have led to an underestimation than an overestimation of TBE risk for travelers. Indeed, our calculations included all Israeli tourists traveling in all seasons, whereas as shown in the 4 cases reported here as well (Table 1), TBE risk is seasonal: were only summer tourists considered, incidence rates of travel-related TBE probably would have been even higher.

Table 2. Calculated incidence of travel-related TBE for selected countries, Europe*

Study (source country, years of study [reference])	Country of travel	Population studied	TBE incidence		
			Cases/tourist entries	Cases/person-weeks	Cases/100,000 travel-years
Incidence of TBE disease					
This study (Israel, 2006–2014)	Germany	Travelers	1/1,634,192	1/697,700	7.5
	Austria	Travelers	1/732,160	1/393,556	13.2
	Switzerland	Travelers	1/578,052	1/199,102	45.0
	Sweden	Travelers	1/128,642	1/16,270	321.0
	Russia	Travelers	1/855,118	NA	NA
Reusken et al. (Netherlands [7])	Austria	Travelers	NA	1/1,380,952	3.8
Incidence of TBE seroconversion					
Sanchez et al. (USA [8])	Bosnia-Herzegovina	Military personnel	NA	1/12,501	416.0, 8.3†
McNeil et al. (USA [9])	Germany	Military personnel	NA	1/4,775	1,088.9, 21.8†

*NA, not available; TBE, tick-borne encephalitis.

†Estimated incidence of clinical disease if 98% of infections are subclinical.

It is interesting to compare the data presented here on TBE to another travel-related, vaccine-preventable flavivirus: Japanese encephalitis (JE). The risk for JE among travelers is considered low: $<1/1 \times 10^6$ travelers staying 1 month (which equals an incidence lower than 1.2 cases/100,000 travelers/year of travel) (2). Our findings, as well as those of previous reports, suggest that the risk posed by TBE far exceeds that posed by JE to travelers. Only 1 case of JE in an Israeli traveler has been reported in >2 decades (15), whereas at least 4 TBE cases were diagnosed during the past 9 years. Similar to JE, TBE had been documented to cause severe and fatal illness among travelers, but whereas JE vaccines for travelers are promoted by most government advisory boards in developed countries, very little is done regarding TBE vaccination. This difference probably underlies the fact that in Israel, for example, during 2012–2014, a total of 46,773 JE vaccine doses were distributed, whereas only 960 TBE vaccine doses were sold during the same period (E. Schwartz, unpub. data).

In conclusion, actual incidence of TBE among Israeli travelers to Austria, Germany, Sweden, and Switzerland appears to be higher than the threshold recommended by WHO for universal TBE vaccination. Vaccination should be recommended to all travelers with potential exposure to tick habitat in these destinations. However, TBE vaccine appears to be greatly underutilized among Israeli travelers.

Dr. Meltzer is a specialist in infectious diseases and travel and tropical medicine who practices at the Chaim Sheba Medical Center and at the Sackler School of Medicine at Tel Aviv University. His main areas of interest are travel-related, vector-borne, and parasitic diseases.

References

1. European Centre for Disease Prevention and Control. Epidemiological situation of tick-borne encephalitis in the European Union and European Free Trade Association countries. 2012 [cited 2016 Sep 29]. <http://ecdc.europa.eu/en/publications/Publications/TBE-in-EU-EFTA.pdf>
2. Centers for Disease Control and Prevention. Health information for international travel. 2016 [cited 2016 Sep 29]. <http://wwwnc.cdc.gov/travel/yellowbook/2016/table-of-contents>
3. Israeli Ministry of Health. Guidance for travelers abroad. 2013 [cited 2016 Sep 29]. http://www.health.gov.il/Subjects/vaccines/Vaccines_abroad/Documents/travel2013.pdf
4. World Health Organization. International travel and health: situation as on 1 January 2012 [cited 2016 Sep 29]. http://who.int/ith/ITH_EN_2012_WEB_1.2.pdf?ua=1
5. Steffen R. Epidemiology of tick-borne encephalitis (TBE) in international travellers to Western/Central Europe and conclusions on vaccination recommendations. *J Travel Med.* 2016;23:taw018.
6. European Commission. Commission implementing decision of 8 August 2012 amending decision 2002/253/EC laying down case definitions for reporting communicable diseases to the community network under decision no 2119/98/EC of the European Parliament and of the Council (2012/506/EU). *Official Journal of the European Union.* 2012;(262) [cited 2016 Oct 18] <http://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2012:262:SOM:EN:HTML>
7. Reusken C, Reimerink J, Verduin C, Sabbe L, Cleton N, Koopmans M. Case report: tick-borne encephalitis in two Dutch travellers returning from Austria, Netherlands, July and August 2011. *Euro Surveill.* 2011;16:20003.
8. Sanchez JL Jr, Craig SC, Kohlhase K, Polyak C, Ludwig SL, Rumm PD. Health assessment of U.S. military personnel deployed to Bosnia-Herzegovina for operation joint endeavor. *Mil Med.* 2001;166:470–4.
9. McNeil JG, Lednar WM, Stansfield SK, Prier RE, Miller RN. Central European tick-borne encephalitis: assessment of risk for persons in the armed services and vacationers. *J Infect Dis.* 1985;152:650–1. <http://dx.doi.org/10.1093/infdis/152.3.650a>
10. STATcube—Statistical Database of STATISTIC AUSTRIA [cited 2016 Jan 25]. <http://statcube.com/statistik.at/ext/statcube/jsf/dataCatalogueExplorer.xhtml>
11. German National Tourist Board. GNTB market research [cited 2016 Jan 25]. http://www.germany.travel/us/trade/market-research/dzt_marktforschung_1.html
12. Statistik Schweiz. Hotellerie: country of origin [cited 2016 Jan 25]. <http://www.bfs.admin.ch/bfs/portal/de/index/themen/10/03/blank/key/02/01.html>
13. Haditsch M, Kunze U. Tick-borne encephalitis: a disease neglected by travel medicine. *Travel Med Infect Dis.* 2013;11:295–300. <http://dx.doi.org/10.1016/j.tmaid.2013.07.003>
14. World Health Organization. Vaccines against tick-borne encephalitis: WHO position paper. *Wkly Epidemiol Rec.* 2011;86:241–56.
15. Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. *Clin Infect Dis.* 2002;35:183–8. <http://dx.doi.org/10.1086/341247>

Address for correspondence: Eyal Meltzer, The Center for Geographic Medicine and Department of Medicine C, The Chaim Sheba Medical Center, Tel Hashomer 52621, Israel; email: emeltzer@post.tau.ac.il

Travel-Related Tick-Borne Encephalitis, Israel

Technical Appendix

Clinical and Epidemiologic Information about Tick-borne Encephalitis in Travelers Returning to Israel

Case-patient 1: A 25-year-old previously healthy Israeli woman had traveled on June 2014 for 3 days to Austria, where she resided near Salzburg. The only time she had spent outdoors was a short hike for <1 hour in a wooded area, where she recalled sitting barefoot in a forest clearing. The same night she removed 2 ticks from behind her right knee. A week later, fever, severe headache, and vomiting developed. After 2 days, diplopia developed; physical examination revealed nuchal rigidity and paralysis of the fourth cranial nerve. Lumbar puncture showed mixed lymphocytic-neutrophilic pleocytosis and elevated protein. Within a day, stupor, aphasia, and intermittent strabismus developed. In the next few days, her fever resolved and consciousness improved but she remained quadriparetic. After 2.5 months of rehabilitation, there was still left hand monoparesis and some cognitive and mental impairment. On follow-up after 6 months, she still had impaired concentration and decreased ability to study and was treated for depression.

Case-patient 2: A 26-year-old previously healthy Israeli man had traveled to Germany and Switzerland in September 2012. His itinerary began with 4 days of hiking and cycling in rural areas in Baden-Württemberg; his later travel in the Alps at various heights (both above and below 1,500 m) was motorized, with less exposure to wooded areas. Two weeks after his return fever, diarrhea, and cough developed. After a week his fever resolved; however, mouth numbness, difficulty eating solid food, and a change in taste developed. Physical examination showed bilateral facial nerve paralysis. Lumbar puncture revealed borderline abnormalities in cerebrospinal fluid. serology showed seroconversion to tickborne encephalitis (TBE) and was

negative for Lyme disease and for West Nile virus (WNV). He was treated with physiotherapy 4 months later was fully recovered.

Case-patient 3: A 39-year-old previously healthy Israeli man had resided since May 2011 for 4 months in a village northwest of Stockholm, Sweden. A month before his return to Israel, he had onset of low fever, which resolved within 3 weeks. However, 10 days later, fever recurred, accompanied by difficulty in speech and some degree of confusion. He was hospitalized in Sweden: a lumbar puncture revealed lymphocytic pleocytosis. After a few days, his general condition improved. On his return, right peripheral facial nerve palsy was present on physical examination. Blood serology for TBE IgG and IgM was positive in Sweden, as well as in Israel. Serology for WNV and Lyme disease were negative. He was treated with physiotherapy for 4 months and fully recovered after 3 months.

Case-patient 4: A 15-year-old previously healthy Israeli boy had traveled to Russia for 17 days in August 2010. He spent 14 days in south-central Siberia hiking, and 3 more days in Moscow. Seven days after returning he had onset of fever and vomiting. A day after fever onset, he became confused to a point that he could not recognize his family members and had upper limb cramps. Neurologic examination showed confusion and drowsiness; the physical examination was otherwise normal. Lumbar puncture showed mild mixed lymphocytic and neutrophilic pleocytosis, elevated protein, and low glucose. Brain magnetic resonance imaging showed minimal thickening of the cortex in the temporal-occipital and subinsular areas. Serology for TBE was positive for IgG and IgM. Over the next few days, his neurologic status improved, and a follow-up visit a month later showed complete resolution of all neurologic symptoms without sequelae.